<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00735345</url>
  </required_header>
  <id_info>
    <org_study_id>AGMT_ECa</org_study_id>
    <secondary_id>EudraCT Nr. 2008-001016-21</secondary_id>
    <nct_id>NCT00735345</nct_id>
  </id_info>
  <brief_title>Chemotherapy Induction and Chemoradiotherapy in Patients With Esophageal Carcinoma</brief_title>
  <official_title>Chemotherapy Induction and Chemoradiotherapy Combined With Cetuximab Respectively in Patients With Non-Metastatic Esophageal Carcinoma: A Multicentric Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbeitsgemeinschaft medikamentoese Tumortherapie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Arbeitsgemeinschaft medikamentoese Tumortherapie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is the evaluate the feasibility and safety of chemotherapy induction&#xD;
      treatment combined with cetuximab followed by chemoradiotherapy combined with cetuximab in&#xD;
      the treatment of patients with non-metastatic esophageal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with a locoregional carcinoma of the esophagus or gastro-esophageal junction have a&#xD;
      low survival prognosis following surgical resection. In studies published to date no positive&#xD;
      effect upon overall survival could be demonstrated for preoperative chemotherapy or&#xD;
      chemoradiotherapy. However, patients with a complete remission following preoperative therapy&#xD;
      show prolonged survival.&#xD;
&#xD;
      This study design is based upon decreasing primary tumour and preventing oder delaying&#xD;
      micrometastases by means of a chemo induction therapy, increasing R0 resection rates and&#xD;
      preventing local recurrence by means of preoperative chemoradiotherapy, increasing the&#xD;
      radiosensitivity of tumour cells through treatment combination with cetuximab, surgical&#xD;
      resection of the locoregional primary tumour or definitive radiochemotherapy in case the&#xD;
      primary tumour is inoperable.&#xD;
&#xD;
      The aim of this study is therefore to evaluate the feasibility and safety of a 3-staged&#xD;
      therapy approach including an EGFR antibody in the treatment of patients with potentially&#xD;
      resectable esophageal cancer, as well as the evaluation of objective response rates to this&#xD;
      preoperative therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    because of safety concerns the study was terminated prematurely&#xD;
  </why_stopped>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Duration of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of complete remissions and resection rate</measure>
    <time_frame>Duration of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of toxicities</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Quality of Life</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemo induction therapy followed by chemoradiotherapy and surgical resection or definitive radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>750 mg/m2/d C.I. i.v.d1-5, d29-33 and 300 mg/m2/d C.I. i.v. on the days of radiotherapy</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>15 mg/m2/d i.v. d1-5, d29-33</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taxotere</intervention_name>
    <description>75 mg/m2/d i.v. d1 and d29, 15 mg/m2/d i.v. on d57, d64, d71 and d78</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>Docetaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Cetuximab: 400 mg/m2 i.v. d1; 250mg/m2 weekly d8 through d85</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation during chemoradio-immunotherapy</intervention_name>
    <description>39.6 Gy total dose</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  histologically confirmed esophageal cancer (squamous cell carcinoma)&#xD;
&#xD;
          -  measurable, non-metastatic disease (uT1-4)&#xD;
&#xD;
          -  no previous cancer therapy (chemotherapy, radiotherapy or resection)&#xD;
&#xD;
          -  life expectancy &gt; 3 months&#xD;
&#xD;
          -  age &gt; 18 years&#xD;
&#xD;
          -  WHO Status ≤ 2&#xD;
&#xD;
          -  negative pregnancy test for women of child-bearing potential, and use of adequate&#xD;
             contraception&#xD;
&#xD;
          -  hematological status: neutrophiles ≥ 1,5x10E9/L, thrombocytes ≥ 100x10E9/L&#xD;
&#xD;
          -  adequate renal function: serum creatinine ≤ 1,5 x ULN&#xD;
&#xD;
          -  adequate liver function: alkaline phosphatase &lt; 2,5 x ULN, total bilirubin &lt; 1,5 x ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant or nursing women&#xD;
&#xD;
          -  women of child-bearing potential without adequate contraception&#xD;
&#xD;
          -  concomitant anti-tumoral therapy except study mandated procedures&#xD;
&#xD;
          -  cervical esophageal cancer or diagnosis of metastases&#xD;
&#xD;
          -  participation in other clinical trials within the last 30 days&#xD;
&#xD;
          -  history of malignant disease within the last 5 years&#xD;
&#xD;
          -  peripheral neuropathy (NCI CTC ≥ grade 1)&#xD;
&#xD;
          -  concurrent active and serious non-malignant diseases: uncontrolled heart&#xD;
             insufficiency, angina pectoris, hypertension or arrhythmias, liver disease,&#xD;
             significant neurological or psychiatric conditions&#xD;
&#xD;
          -  active infections&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Eisterer, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medizinische Universitaet Innsbruck</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Landeskrankenhaus Feldkirch</name>
      <address>
        <city>Feldkirch</city>
        <zip>A-6806</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Graz</name>
      <address>
        <city>Graz</city>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.ö. Landeskrankenhaus Leoben</name>
      <address>
        <city>Leoben</city>
        <zip>A-8700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik f. Innere Medizin III</name>
      <address>
        <city>Salzburg</city>
        <zip>A-5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Barmherzige Brueder St. Veit a.d. Glan</name>
      <address>
        <city>St. Veit/ Glan</city>
        <zip>A-9300</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Kreuzschwestern Wels GmbH</name>
      <address>
        <city>Wels</city>
        <zip>A-4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>August 13, 2008</study_first_submitted>
  <study_first_submitted_qc>August 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2008</study_first_posted>
  <last_update_submitted>March 6, 2015</last_update_submitted>
  <last_update_submitted_qc>March 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2015</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Richard Greil</name_title>
    <organization>Arbeitsgemeinschaft medikamentoese Tumortherapie</organization>
  </responsible_party>
  <keyword>Esophageal cancer</keyword>
  <keyword>Pre-operative</keyword>
  <keyword>Chemo-immunotherapy</keyword>
  <keyword>Radiochemo-immunotherapy</keyword>
  <keyword>EGFR</keyword>
  <keyword>Radiosensitivity</keyword>
  <keyword>Resection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

